Zobrazeno 1 - 10
of 416
pro vyhledávání: '"HISAO IMAI"'
Autor:
Kosuke Hashimoto, Kyoichi Kaira, Hisao Imai, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Yu Miura, Kunihiko Kobayashi, Hiroshi Kagamu, Ichiei Kuji
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Two-deoxy-2-[fluorine-18]-fluoro-d-glucose (18F-FDG) positron emission tomography (PET) is useful for detecting malignant lesions; however, the clinical significance of cardiac 18F-FDG uptake in patients with cancer remains unclea
Externí odkaz:
https://doaj.org/article/449e6de7ae8843a09579cd9494df971a
Autor:
Ryo Taguchi, Kyoichi Kaira, Yu Miura, Tetsuya Umesaki, Atsuto Mouri, Hisao Imai, Hiroshi Kagamu, Masanori Yasuda, Yoshikatsu Kanai, Hiroyuki Nitanda, Hironori Ishida, Hirozo Sakaguchi
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e37414- (2024)
Background: The L-type amino acid transporter (LAT1) exhibits significantly increased expression within tumor cells across various neoplasms. However, the clinical significance of LAT1 expression in patients with pleural mesothelioma (PM) remains unc
Externí odkaz:
https://doaj.org/article/31c2c6cffc66424fb45f3b27bb180f1b
Autor:
Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai, Ichiro Naruse, Hiroyuki Yamaguchi, Miki Itai, Kohei Taguchi, Megumi Uchida, Noriaki Sunaga, Toshitaka Maeno, Koichi Minato, Hiromi Tomono, Daiki Ogawara, Hiroshi Mukae, Yu Miura, Ayako Shiono, Atsuto Mouri, Hiroshi Kagamu, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are limited. Therefore, the pr
Externí odkaz:
https://doaj.org/article/136751bf535d4857a7d70d282fd7c6bf
Autor:
Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Kunihiko Kobayashi, Tomonori Kawasaki, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 29, Pp 2950-2961 (2023)
Abstract Background Vascular endothelial growth factor (VEGF) has been identified as one of the resistant mechanisms to epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs). However, the relationship between the efficacy of osi
Externí odkaz:
https://doaj.org/article/fece6ef98b054e98ae461b7a3a7353f3
Autor:
Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi, Takashi Osaki, Yosuke Miura, Yukihiro Umeda, Akihiro Ono, Hiroyuki Minemura, Yutaka Yamada, Junichi Nakagawa, Yuki Kozu, Hirokazu Taniguchi, Hiromitsu Ohta, Takashi Kasai, Kyoichi Kaira, Hiroshi Kagamu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2567-2578 (2023)
Abstract Background Factors predicting the response to pembrolizumab plus platinum and pemetrexed combination therapy (Pemb‐Plt‐PEM) in nonsquamous non‐small cell lung cancer (non‐sq NSCLC) are unclear. We investigated the Glasgow Prognostic
Externí odkaz:
https://doaj.org/article/94316acf290f494398a776598e298791
Autor:
Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho, Hiroshi Tanaka, Hiroyuki Yamaguchi, Takayuki Kaburagi, Hisao Imai, Keita Mori, Junya Ohtake, Hiroaki Okamoto
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14988-14999 (2023)
Abstract Introduction Cisplatin plus pemetrexed followed by pemetrexed is an efficacious platinum combination regimen for advanced non‐squamous, non‐small cell lung cancer (NSCLC). Data regarding the addition of bevacizumab, especially in mainten
Externí odkaz:
https://doaj.org/article/eba439d047e748209a1bb12b174b1fd1
Autor:
Kyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda, Satoshi Watanabe, Kosuke Ichikawa, Shin Yanagisawa, Norimitsu Kasahara, Tetsuya Higuchi, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Iizuka, Tamotsu Ishizuka, Koichi Minato, Satoshi Suda, Hiroshi Kagamu, Keita Mori, Nobuhiko Seki, Ichiei Kuji
Publikováno v:
Cancer Imaging, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Purpose To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monotherapy in patients with
Externí odkaz:
https://doaj.org/article/561845a46d094745b5ca09fd534e42c6
Autor:
Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, Kousuke Hashimoto, Yu Miura, Ayako Shiono, Atsuto Mouri, Hisao Imai, Kunihiko Kobayashi, Masanori Yasuda, Hiroshi Kagamu
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Aim Tumor-infiltrating lymphocytes (TILs) in the tumor and stroma are expected to accurately predict the efficacy of programmed death-1 (PD-1) blockade therapy. However, little is known about the prognostic significance of TILs in first-line
Externí odkaz:
https://doaj.org/article/51df83129f1f4f2b811f207816e4829f
Autor:
Ayako Shiono, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Hiroyuki Minemura, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Hiroki Takechi, Ou Yamaguchi, Atsuto Mouri, Kyoichi Kaira, Hirokazu Taniguchi, Koichi Minato, Hiroshi Kagamu
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 73-83 (2023)
Abstract Purpose The aim of this study was to assess the effectiveness and tolerability of atezolizumab plus carboplatin and etoposide combination chemotherapy in elderly patients with extensive‐disease (ED) small‐cell lung cancer (SCLC). Methods
Externí odkaz:
https://doaj.org/article/7b714a5a6ae74295a24b9195992b391e
Autor:
Ken Masubuchi, Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Hiroyuki Minemura, Yoshiaki Nagai, Yutaka Yamada, Takayuki Kishikawa, Yukihiro Umeda, Ayako Shiono, Hiroki Takechi, Jun Shiihara, Kyoichi Kaira, Kenya Kanazawa, Hirokazu Taniguchi, Takayuki Kaburagi, Hiroshi Kagamu, Koichi Minato
Publikováno v:
Thoracic Cancer, Vol 13, Iss 19, Pp 2776-2785 (2022)
Abstract Background The effect of first‐line chemotherapy on overall survival (OS) may be significantly influenced by subsequent therapy for patients with extensive disease small cell lung cancer (ED‐SCLC). Therefore, we evaluated the relationshi
Externí odkaz:
https://doaj.org/article/64e6b20ba7e5445abb1fbb3bc51921e4